RegulatoryCompany release

Scholar Rock starts US launch of SMA therapy Isembyld; EU and Japan reviews under way

🇺🇸 Scholar Rock Holding Corp (SRRK) · Tue 10 Nov 2026

After FDA approval in September, Scholar Rock reported $0.6 million in first launch revenue, with EMA and PMDA reviews advancing and a priority review voucher sale agreed for $205 million.

Scholar Rock reported third-quarter 2026 results on 10 November, confirming that Isembyld (apitegromab-mstn) is now on the US market. The FDA approved the product on 11 September 2026 for patients with spinal muscular atrophy (SMA) aged two years and older who are receiving an SMN2-targeted therapy.

The initial launch contributed $0.6 million in revenue. The company's summary gives no further commercial detail, such as uptake, pricing or patient numbers.

In Europe, the European Medicines Agency validated Scholar Rock's resubmitted marketing authorisation application in October 2026. The company expects an opinion from the Committee for Medicinal Products for Human Use (CHMP) in the first half of 2027. Validation means the application is complete enough for the formal scientific assessment to begin; it does not indicate any view on the outcome.

In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) has accepted the filing under priority review. Scholar Rock has also agreed to sell its priority review voucher for $205 million.

What it means for your team

  • Regulatory teams tracking SMA should note the CHMP opinion timetable of H1 2027 for the resubmitted EU application.
  • Isembyld's US label is restricted to patients aged two and older who are on an SMN2-targeted therapy, which defines the approved use alongside existing treatments.
  • Market-access and pharmacovigilance teams may see early US real-world use build from a very small base, given the $0.6 million of first-period revenue.
  • The $205 million voucher sale shows the continuing market value of US priority review vouchers.

Company's press release (SEC filing): Scholar Rock Holding Corp ↗

Article written by VigiEye from the official source (Scholar Rock Holding Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →